CURIS INC CRIS

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).

Last close 0.39 2026-10-23
Market cap $807.4K 2026-06-30 share count
52-week range 0.33 - 33.00

Valuation FY2025 figures against the last close

P/S0.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.58

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $9.4M$10.9M$10.0M$10.2M$10.6M$10.8M$10.0M$10.4M$9.9M$7.5M
R&D —————————$18.0M
SG&A $14.0M$16.8M$18.6M$19.6M$17.3M$12.1M$11.6M$14.8M$14.1M$15.6M
Total operating expenses $42.3M$55.5M$58.4M$63.2M$52.7M$35.7M$34.4M$39.8M$59.7M$65.6M
Operating income -$5.7M-$44.5M-$48.3M-$53.0M-$42.1M-$24.9M-$24.4M-$29.3M-$49.8M-$58.0M
Interest expense ————$0$0$791.0K$3.9M$4.0M$2.8M
Pre-tax income -$7.6M-$43.4M————————
Income tax $0$0————————
Net income -$7.6M-$43.4M-$47.4M-$56.7M-$45.4M-$29.9M-$32.1M-$32.6M-$53.3M-$60.4M
EPS, basic -0.58-6.88-8.96-12.140.50-0.61-0.97———
EPS, diluted -0.58-6.88-8.96-12.140.50-0.61-0.97-0.98-1.79-0.45
Shares, diluted (wtd. avg.) 13.2M6.3M5.3M4.7M91.6M48.7M33.2M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $5.1M$20.0M$27.2M$20.3M$40.7M$130.4M$16.4M$23.8M$38.4M$26.0M
Short-term investments —$0$29.7M$66.0M$75.9M$38.9M$5.1M$634.0K$21.9M$18.4M
Receivables $0$3.3M$2.8M$3.0M$3.2M$3.0M$3.2M$2.9M$3.1M$2.5M
Total current assets $6.9M$26.4M$60.9M$92.1M$122.4M$172.8M$25.0M$28.0M$64.3M$48.2M
Property, plant and equipment $62.0K$231.0K$434.0K$689.0K$505.0K$663.0K$154.0K$267.0K$366.0K$413.0K
Goodwill $9.0M$9.0M$9.0M$9.0M$9.0M$9.0M$9.0M$9.0M$9.0M$9.0M
Total assets $20.0M$41.3M$77.3M$108.8M$162.3M$204.4M$35.1M$37.4M$73.8M$57.8M
Accounts payable $5.6M$3.0M$3.2M$3.2M$6.4M$4.2M$4.5M$2.9M$5.4M$5.9M
Short-term debt $0$7.6M$8.5M—$0$557.0K$0$6.9M$5.9M$4.9M
Total current liabilities $14.1M$19.0M$22.0M$10.0M$13.4M$10.1M$6.5M$13.2M$14.1M$13.5M
Long-term debt ——————$900.0K$28.6M$35.7M$14.9M
Total liabilities $14.5M$47.3M$57.6M$62.3M$71.6M$73.7M$69.0M$41.9M$49.8M$28.5M
Retained earnings -$1.25B-$1.24B-$1.20B-$1.15B-$1.09B-$1.05B-$1.02B-$984.8M-$952.3M-$898.9M
Total equity $5.5M-$6.0M$19.7M$46.6M$90.7M$130.7M-$33.9M-$4.5M$24.0M$29.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$27.2M-$39.6M-$38.4M-$54.3M-$37.6M-$25.7M-$26.2M-$30.1M-$48.4M-$35.8M
Stock-based compensation $4.0M$5.9M$6.0M$6.8M$5.3M$2.7M$2.7M$3.9M$5.4M$4.3M
Capital expenditure ——$0$416.0K$0$677.0K$41.0K$85.0K$188.0K$329.0K
Investing cash flow $2.5M$29.4M$37.8M$33.0M-$47.9M-$49.0M-$4.5M$21.4M-$3.6M$30.1M
Financing cash flow $9.8M$3.4M$7.6M$867.0K-$4.2M$188.8M$23.3M-$6.0M$64.2M-$1.4M
Buybacks ————————$1.5M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001108205-26-000053.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -80M -60M -40M -20M 0 20M Revenue, FY2016: 7.5M Net income, FY2016: -60.4M Revenue, FY2017: 9.9M Net income, FY2017: -53.3M Revenue, FY2018: 10.4M Net income, FY2018: -32.6M Revenue, FY2019: 10M Net income, FY2019: -32.1M Revenue, FY2020: 10.8M Net income, FY2020: -29.9M Revenue, FY2021: 10.6M Net income, FY2021: -45.4M Revenue, FY2022: 10.2M Net income, FY2022: -56.7M Revenue, FY2023: 10M Net income, FY2023: -47.4M Revenue, FY2024: 10.9M Net income, FY2024: -43.4M Revenue, FY2025: 9.4M Net income, FY2025: -7.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $7.5M $9.9M $10.4M $10.0M $10.8M $10.6M $10.2M $10.0M $10.9M $9.4M
Gross profit — — — — — — — — — —
Net income -$60.4M -$53.3M -$32.6M -$32.1M -$29.9M -$45.4M -$56.7M -$47.4M -$43.4M -$7.6M

Recent filings and events

  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Charter or fiscal year changed Item 5.03
  • Charter or fiscal year changed Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Shareholder rights changed Item 3.03
  • Charter or fiscal year changed Item 5.03
  • Shareholder vote Item 5.07
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Delisting notice Item 3.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%